Pfizer buys oncology drug manufacturer

Pharmaceutical Corporation Pfizer buys oncology drugs manufacturer Medivation for 14 billion dollars. Both sides already accepted the deal; conversation lasted for a couple of months. Medivation purchase provides Pfizer income, strengthen the business and allows becoming leading oncology drug manufacturer, also this deal positively affects on corporation stock price.

Pfizer stocks increased for the end on June on 3%. Awaits a positive trend, after purchase announcement. For traders where will be a great chance to close income deals. Trading will be available during American session, from 14:40 to 21:00 GMT time.

The news is only for informational purposes and cannot be construed as an offer or indication of the commission of certain transactions in the financial and commodity markets.